Prothena Corporation (NASDAQ:PRTA) reported its Q2 results, with $1.3 million in collaboration revenue, $44.5 million in OpEx, and $510.1 million in cash.
The company reiterated its prior full-year financial guidance and expects net cash use for operations and investing activities to be in the range of $120-132 million.
Oppenheimer analysts said they remain encouraged by the company’s unique approach with an emphasis on epitope and expertise in understanding misfolded proteins as differentiating. Near term, the analysts expect PRX005 Ph1 top-line data and PRX012 to start the Ph1 MAD study in 2022.
Follow us on Google news for more updates and News